secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001193125-25-043405
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025
------------------------------------------------------------------------

- Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.
- Phase 2a trial of RAP-219 in refractory focal epilepsy to report topline results in Q3 2025.
- Phase 2a trial of RAP-219 in bipolar mania to initiate in Q3 2025 with data expected in H1 2027.
- Sevigny brings 15+ years experience from Roche, Biogen, Novartis, and Merck to lead clinical strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/0001193125-25-043405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/d876788d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-043405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer